Travere Therapeutics (TVTX) Tops Q3 EPS by 333c

Travere Therapeutics (NASDAQ: TVTX) reported Q3 EPS of $2.27, $3.33 better than the analyst estimate of ($1.06). Revenue for the quarter came in at $37.09 million versus the consensus estimate of $57.78 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Oracle (ORCL) Tops Q1 EPS by 19c, Beats on Revenue; Beats on Cloud Revenue, Offers Q3 EPS Guidance
• Incyte (INCY) Reiterated at Neutral by Cantor Fitzgerald After Management Chat